Compare NBHC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | AGIO |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | 488 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2012 | 2013 |
| Metric | NBHC | AGIO |
|---|---|---|
| Price | $37.95 | $27.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $44.33 | $35.63 |
| AVG Volume (30 Days) | 313.4K | ★ 1.6M |
| Earning Date | 01-21-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.15 | N/A |
| Revenue | ★ $405,867,000.00 | $44,791,000.00 |
| Revenue This Year | $8.48 | $28.75 |
| Revenue Next Year | $28.10 | $139.45 |
| P/E Ratio | $12.03 | ★ N/A |
| Revenue Growth | 1.03 | ★ 36.26 |
| 52 Week Low | $32.83 | $22.24 |
| 52 Week High | $44.93 | $46.00 |
| Indicator | NBHC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 40.40 | 44.37 |
| Support Level | $39.35 | $26.66 |
| Resistance Level | $40.68 | $27.61 |
| Average True Range (ATR) | 0.61 | 1.13 |
| MACD | -0.29 | 0.61 |
| Stochastic Oscillator | 8.36 | 50.17 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.